A double-blind, placebo-controlled clinical study of Nilotinib (Tasigna®) in patients with Parkinson's disease

Trial Profile

A double-blind, placebo-controlled clinical study of Nilotinib (Tasigna®) in patients with Parkinson's disease

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2016 New trial record
    • 14 Sep 2016 According to an Inhibikase Therapeutics media release, the Investigational New Drug (IND) application filed by the company has received FDA clearance to initiate this clinical trial and should begin patient evaluation for enrollment within a few months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top